No Abstract

No Abstract

We have clinically examined thirty patients with age ranging between 39 to 85 years old. We observed resting Tremor and Brakykinesia in 100% of patients examined and a family history of Parkinson Disease (PD) in 12%. We have found the following comorbidities: arterial hypertension 21%, diabetes 21%, language disorders 21%, neurobehavioral dysfunctions: 12%, neurosensory disorders, (hypoacusia) 12%, dizziness 8%, respiratory diseases 8%, constipation 8% and sleep disorders 8%. The following risks factors environmental conditions, stress, toxics, and previous cerebrovascular accident (1%) were observed. Parkinson disease motor and non-motor symptoms are discussed in details. PD can be associated with nneurobehavioral disorders (depression, anxiety), cognitive impairment (senile dementia), autonomic dysfunction, stress and aggressivity. PD ethiopathogenesis remains to be elucidated and has been connected to genetic, environmental and immunologic conditions. A differential diagnosis of PD with atypical parkisonian syndromes, such as progressive supranuclear palsy, multiple system atrophy, Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD) is included.

We report long-term outcomes after one-stage, surgical repair, at an 11-year-old, girl with pulmonary atresia with a ventricular septal defect and anomalous origin of the left coronary artery from the right coronary artery, crossing the right ventricular outflow tract. The operation was carried out with the remodeling of the right ventricle, using a swine valved conduit prosthesis (22mm). Twenty-nine years later, the patient is in excellent clinical condition, CF I (NYHA), with normal peripheral oxygen saturation. Recent invasive and not invasive imaging show: the absence of intracardiac shunt, despite presenting prosthesis calcification and signs of mild double lesion of the prosthetic valve. The pulmonary flow is directed uniformly for both lungs. Patients undergoing the implantation of valved conduits during childhood, present mismatch, after a few years of follow-up, and are required to undergo frequent reoperations. In this patient, the indication of a Blalock-Taussig shunt, during childhood, allowed to postpone the surgery and implant a valved conduit with a larger diameter, achieving a long follow-up with a single prosthetic implant.

Objectives: The aim of this study was to determine if Lysyl Oxidase Like 1 (LOXL1) and Fibulin-5 (Fib5), two crucial proteins in the elastin metabolism pathway, are detectable in the vaginal secretions of women with and without Pelvic Organ Prolapse (POP). We then sought to quantify levels of these proteins in relation to prolapse. Methods: Vaginal secretions were obtained from 48 subjects (13 (27.1%) without and 35 (72.9%) with POP-Q Stage 2-4 prolapse). Eleven (22.9%) subjects were premenopausal and 37 (77.1%) were postmenopausal. Presence of LOXL1 and Fibulin-5 within specimens were first identified via western blotting. Enzyme-Linked Immunosorbent Assays specific for LOXL1 and Fibulin-5 were conducted to quantify total protein secretion. Results: LOXL1 was detected in 45/48 (93.8%) and Fibulin-5 was seen in 24/48 (50%) of subjects. LOXL1 values were lower in women without prolapse (13.3 ng/100 mg median, 24.4 IQR) vs. those with prolapse (26.4 ng/100 mg, 102.2 IQR). On multivariate analysis controlling for age, women with prolapse had a 544% (p=0.0042 higher LOXL1 protein level compared to those without. There was no significant differences in LOXL1 or Fibulin-5 protein detection with relation to menopausal status in bivariate analysis. Conclusions: This is the first published report of non-invasively measuring urogenital LOXL1 and Fibulin-5. In vaginal secretions, LOXL1 protein is higher in subjects with POP than those without.